VTE and the Hospital Pharmacist: Implementing Optimal Management Protocols

Sponsored by North American Center for Continuing Medical Education, LLC

Target Audience

This activity is designed for hospital-based pharmacists.

Learning Objectives

After completing this activity, participants should be able to:

Develop methods to assure timely venous thromboembolism (VTE) risk assessment and appropriate use of VTE prophylaxis in hospitalized patients
Implement protocols for VTE management, including appropriate monitoring and dosing strategies
Incorporate the latest guidelines and performance measures into clinical practice to optimize outcomes

Credit Eligibility

To be eligible for documentation of credit, participants must participate in the full educational activity, including question and answer session, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: October 2, 2008

Expiration Date: October 2, 2009

Estimated time to complete: 1 hour

There is no fee associated with this activity.

Lecture Components

The slide presentation with audio, question and answer session, pre-test, post-test, and evaluation form are available as a click-through via the menu at the top of the page.

CPE Accreditation

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UPN 276-999-08-011-H01-P).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact John Savage, Director, Medical Education, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535, or by e-mail at jsavage@naccme.com. The Director of Medical Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Vice President, Medical Education, NACCME, may be made for a second level of review.

Grant Support

This program is supported by an educational grant from sanofi-aventis U.S.

Faculty

Paul P. Dobesh, PharmD, FCCP, BCPS
Associate Professor of Pharmacy Practice
College of Pharmacy
University of Nebraska Medical Center
Omaha, Nebraska

Ann Wittkowsky, PharmD
Clinical Professor of Pharmacy
University of Washington
School of Pharmacy
Director of Anticoagulation Services
University of Washington Medical Center
Seattle, Washington

Independent Clinical Reviewer

Kenneth A. Bauer, MD, Professor of Medicine, Harvard Medical School, Director, Thrombosis Clinical Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Planning Committee

The planning committee comprises Drs. Bauer, Dobesh, and Wittkowsky; and Kristin Dickie, Mary Johnson, Randy Robbin, and John Savage, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr. Bauer: Consultant—Bayer; Employee/officer/board member—GTC Biotherapeutics
Dr. Dobesh: Consultant—CV Therapeutics, Eli Lilly and Company, sanofi-aventis U.S., The Medicines Company; Speakers bureau—sanofi-aventis U.S.
Dr. Wittkowsky: Consultant—Boehringer Ingelheim Pharmaceuticals, GlaxoSmithKline; Speakers bureau—sanofi-aventis U.S.

Kristin Dickie, Mary Johnson, Randy Robbin, and John Savage, NACCME have disclosed that they have no relevant financial relationships with any commercial interest.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentation.

The faculty has disclosed that no off-label/unapproved uses of drugs or devices will be discussed.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2008 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the North American Center for Continuing Medical Education.